Zydus gains China NMPA approval for venlafaxine capsules

Zydus Lifesciences Limited announced on November 11, 2025, that it has received approval from China's NMPA for its Venlafaxine Extended-Release (ER) Capsules in 75 mg and 150 mg strengths. This marks the group's inaugural approval from the NMPA in China, expanding its presence in the Chinese pharmaceutical market.

The Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). The medication is designed to help restore the balance of serotonin and norepinephrine in the brain.

Zydus will produce the approved Venlafaxine ER Capsules at its manufacturing facility in Moraiya, Ahmedabad. This regulatory clearance is expected to contribute to Zydus's international growth strategy by addressing mental health needs in China.